Aldeyra Therapeutics, Inc. announced the expansion of its drug development team with three strategic hires to support upcoming studies for its lead product candidate, NS2. Donna Keith will supervise Chemistry Manufacturing and Controls (CMC), while Dr. Philip L. Piscitelli and Rachel G. Sorensen will supervise clinical development. Collectively, the team has over 40 years of drug development experience with companies such as Genzyme, Vertex Pharmaceuticals, Baxter International, MGI Pharma, Synageva BioPharma, and Verastem.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.395 USD | -6.47% | -12.05% | -3.28% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.28% | 202M | |
+15.85% | 122B | |
+18.91% | 113B | |
+7.25% | 22.84B | |
-18.63% | 20.72B | |
-15.59% | 16.51B | |
-13.76% | 16.39B | |
-43.53% | 15.83B | |
+1.75% | 13.49B | |
+28.07% | 11.67B |
- Stock Market
- Equities
- ALDX Stock
- News Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials